Introduction
Zinc plays various roles in biological systems [1] [2] [3] [4] and in the pathophysiology of central nervous system (CNS) diseases such as Alzheimer's disease, cerebral ischemia and epilepsy. [5] [6] [7] [8] [9] It has been found that it acts either as an anticonvulsant 10 or as a proconvulsant agent 11 depending on the type of seizure, animal species and convulsant agents. [12] [13] [14] It has been shown that intracerebroventricular injection of zinc not only increases audiogenic seizure susceptibility in mice 15 but also causes epileptic seizures in rats. 11, [16] [17] [18] On the other hand, audiogenic seizure activity was decreased by subcutaneous injection of zinc. 19 Beside these controversial actions of exogenous zinc, an anticonvulsant action for endogenous zinc has been proposed. 20 Thus, systemic administration of metal chelating agents, DEDTC and diphenylthiocarbazone (dithizone), decreases the lag phase before the induction of seizure by intra-peritoneal (i.p.) injection of kainate or electrical stimulation, which can be explained by their penetration into the brain and binding to the endogenous zinc. [20] [21] [22] [23] Studies with Timm's sulfide-silver staining also revealed reduced zinc content in hippocampus after using mentioned chelating agents. 20, [24] [25] [26] However, the function of vesicular zinc is not well understood. 27 It has been proved that administrating nitric oxide (NO) generators results in accumulation of chelatable zinc in hippocampal neuronal perikarya. 4, 24, 28 In addition, an anticonvulsant role for NO has been reported. 29 More interestingly, cholestasis leads to NO overproduction [30] [31] [32] and also increases levels of hepatic and serum zinc at 24 h after bile duct ligation. 33 On the other hand, pentylenetetrazole (PTZ)-induced seizure threshold has been reported to increase in cholestatic mice and it has been suggested to be due to increased opioidergic tone and NO level.
Zinc has been proven to be anticonvulsant in several studies which indicate that diphenylthiocarbazone (dithizone) and diethyldithiocarbamate (DEDTC), zinc chelating agents, enhance seizure activities. There is also evidence that nitric oxide (NO) generators increase zinc concentration in the brain. On the other hand, the increased level of NO in the nervous system and the consequently increased seizure threshold in cholestatic mice have been well studied. Thus, it could be hypothesized that one of the reasons for the increased seizure threshold in cholestasis is partly the enhanced endogenous zinc concentration, at least in part, due to the overproduction of NO. In this study, we examined the hypothesis that zinc chelating agents might decrease seizure activity to its pre-cholestatic level in bile duct-ligated (BDL) mice. Mice were intra-peritoneally injected with dithizone and diethyldithiocarbamate (DEDTC) before the induction of seizure by pentylenetetrazole (PTZ) and then the seizure activity was recorded. Dose response (dithizone: 5, 30, 100 and 200 mg/kg; DEDTC: 25, 50 and 100 mg/kg) and time course (only for dithizone: 15, 30, 60 and 120 min) studies were performed first. Then, the effects of cholestasis, with and without dithizone injection, on seizure activity were assessed. Proconvulsant effect of dithizone and DEDTC was proved to be dose dependent although time interval between dithizone and PTZ injections did not play any significant role in the seizure activity. Cholestasis decreased seizure activity and increased lag phase before seizure and both effects were decreased by dithizone injection. It is elicited that zinc may mediate the cholestasis-induced decrement in seizure activity. ß 2008 Published by Elsevier Ltd on behalf of British Epilepsy Association.
zinc and opioidergic system. 34, 35 In the present study, we are to assess the effects of zinc chelating agents on the cholestasisinduced changes in seizure activity. As a result, we should expect zinc chelating agents to decrease the cholestasis-induced increment of seizure threshold to its pre-cholestatic level.
Materials and methods

Chemicals
The following drugs were used throughout the study: pentylenetetrazole (Sigma, U.K.), diethyldithiocarbamate (Sigma, U.K.), diphenylthiocarbazone (Fluka, Switzerland), ketamine HCL (Alfasan, Woerden, Holland) and chlorpromazine HCL (Daroupakhsh, Tehran, Iran). Dithizone was dissolved in dimethylsulfoxide (DMSO) and DEDTC was prepared in 0.9% saline and their pH was adjusted to 7-7.4. PTZ was prepared in phosphate buffered saline (18 mg/ml adjusted to pH 7.4). All injections were done intra-peritoneally and in volumes of no more than 10 ml/kg of the body weight of mice.
Animal model of cholestasis: bile duct ligation (BDL)
Male NMRI mice (20-25 g, Pasteur Institute) were used throughout this study. The animals were housed in a temperature-controlled room (25 AE 1 8C) on a 12 h light/dark cycle with free access to food and water. All experiments were performed in accordance with institutional guidelines for animal care and use and also ''Principles of laboratory animal care'' were followed.
Procedures were done as fully described in previous studies at our department. 36, 37 In brief, mice were laparatomized under general anesthesia induced by ketamine (50 mg/kg) and chlorpromazine (10 mg/kg). Bile duct was left in situ after manipulation with forceps in sham-operated animals. In BDL animals, the bile duct was doubly ligated and then abdominal incision was closed in two layers.
Study design
From surgical point of view, each experimental group can be considered into one these three groups: (i) unoperated (UNOP), (ii) sham-operated (SHAM) and (iii) bile duct-ligated (BDL) groups. Each mouse was used only once and each experimental group contained at least seven animals.
Experiment I
A group of unoperated mice was injected PTZ (50 mg/kg) and evaluated as the control group to which vehicle-injected groups were to compare. Five groups of mice were injected DMSO (vehicle group) and different doses of dithizone (5, 30, 100 and 200 mg/kg) intra-peritoneally. After 15 min they were injected PTZ (50 mg/kg). In addition, another four groups of mice were injected vehicle (0.9% saline) or different doses of DEDTC (25, 50 and 100 mg/kg) intraperitoneally. After 30 min these mice were injected PTZ (50 mg/ kg). 20 
Experiment II
Between two metal chelating agents mentioned above (dithizone and DEDTC), dithizone was chosen for the rest of the study because both of them had similar effects on seizure activity in experiment I. In the second experiment constant dosage of dithizone (100 mg/kg) was injected followed by i.p. PTZ (50 mg/ kg) injection after different time intervals: 15, 30, 60 and 120 min.
Experiment III
By having scored the BDL, sham-operated and unoperated controls (60 mg/kg of PTZ) groups, we evaluated the effect of cholestasis on seizure activity. To find the maximum effect of cholestasis on maximum seizure severity score (MSSS) in this model of seizure, four groups of BDL mice were injected PTZ after different time intervals from operation: 24, 48, 72 and 120 h. The strongest effect of cholestasis was revealed to be at 24 h which was selected as the time interval between seizure induction and bile duct ligation in this study. BDL and sham-operated groups were injected PTZ (60 mg/kg) 24 h after operation and the same dosage was injected to the control group. Since the dosage of PTZ was changed (50-60 mg/kg) from experiment II to experiment III, another group was injected dithizone (100 mg/kg) followed by PTZ after 15 min. Eight pretreated mice with DMSO were also injected PTZ (60 mg/kg) as the vehicle-injected group. The fifth group of the experiment was a BDL group which was injected dithizone (100 mg/kg) followed by PTZ (60 mg/kg), 24 h after operation.
Assessment of seizure severity
After i.p. injection of PTZ, mice were observed in clear plastic cages for 30 min and their behavioral seizure activities were scored according to Table 1 . 27 The maximum behavioral response for each mouse was named MSSS. Death was scored as stage 6 only if it was preceded by status epilepticus. Furthermore, the onset of showing forelimb clonus seizure (score 3) or higher scores was considered as ''forelimb clonus latency'' (FCL), an independent index from MSSS.
Statistical analysis
As MSSS did not follow the normal distribution a non-parametric test (Kruskal-Wallis test) was used to test the overall effect of dithizone and DEDTC dosage and time interval on MSSS. Also, another non-parametric test (Mann-Whitney U-test) was used to test the differences in the distribution of MSSS at different doses of dithizone and DEDTC and time intervals between dithizone and PTZ injections. Chi-square test was used to test for the association between using dithizone or DEDTC and the incidence of a certain MSSS. Whenever conditions which permit the use of Chi-square test were not provided, Fisher's exact test was used. Data in all figures are presented as mean AE S.E.M. A P value less than 0.05 was considered as statistically significant. All statistical analyses were performed using the SPSS software, version 13.0.
Results
One day after bile duct ligation, the animals revealed obvious signs of cholestasis (jaundice, dark urine and steatorrhea) and these signs persisted thereafter. The mortality rate was less than 10%. Status epilepticus/death seizure severity score (Kruskal-Wallis test, P < 0.001 and P < 0.01, respectively), while there was not any significant change of FCL by different doses of dithizone and DEDTC (P > 0.05). DMSO and saline as vehicles did not change seizure activity (Mann-Whitney U-test, P > 0.05). No significant effect on MSSS was observed in 5 and 30 mg/kg dithizone-injected groups (Mann-Whitney U-test, P > 0.05) and the minimal injected dose which resulted in significantly increased MSSS compared to vehicle-injected group was 100 mg/kg (P < 0.01). Also, the effect of 200 mg/kg dithizone on MSSS was highly significant (P < 0.001). 25 mg/kg DEDTC had no statistically significant effect on MSSS, while 50 mg/kg (P < 0.05) and 100 mg/kg (P < 0.01) doses were accompanied by significant changes in seizure activity.
Dithizone and DEDTC resulted in significant dose-dependent changes in MSSS
Incidences of different seizure severity scores followed the same pattern as MSSS
The incidences of seizure severity scores 3, 5 and 6, among different groups have been diagrammed in Figs. 1B and 2B. There was a significant increase in the incidences of score 3 (Chi-square test, P < 0.01), scores 5 and 6 (Chi-square test, P < 0.001) due to dithizone injection. 100 mg/kg dosage of dithizone increased the incidence of score 5 (Fisher's exact test, P < 0.01), whereas 200 mg/ kg dosage enhanced both scores 5 and 6 of seizure activities (Fisher's exact test, P < 0.01). Also, incidence of score 3 showed significant increase compared to control group following 200 mg/ kg dithizone injection. DEDTC injection showed an increase only in the incidence of score 5 (P < 0.001). Injection of 100 mg/kg DEDTC was accompanied by increased incidence of score 5 compared to vehicle-injected group (P < 0.01).
Time course study revealed no significant role for time the interval between dithizone injection and seizure induction
From the experiment II onward, the dithizone was chosen between two metal chelating agents used in the experiment I. For selecting a dose of dithizone among those used in the experiment II, we compared the significantly effective doses, 100 and 200 mg/kg. The dose of 200 mg/kg showed statistically significant increase in MSSS compared to the dose of 100 mg/kg (P < 0.01). However, we were not to choose the most effective dose because in the experiment I 7 out of 8 of 200 mg/kg dithizone-injected mice showed score 6, the maximum score, which meant this dose of dithizone (200 mg/kg) was not an ideal dose for the time course study; because if changing the time was going to increase seizure activity, this dose of dithizone would have not been able to detect the difference. Thus, the dosage of 100 mg/kg was used in this stage of the study (time course study). In experiment II, there was no significant difference between groups (Kruskal-Wallis test, P > 0.05) and therefore the 15 min interval was chosen for the experiment III.
Cholestasis resulted in significant decrease of MSSS which was opposed by dithizone administration
As mentioned earlier, the dosage of PTZ was changed from 50 to 60 mg/kg in experiment III. It is well known that cholestasis decreases seizure activity and as the mice in control group, which were injected 50 mg/kg, all showed stage 2 of seizure activity, it was nearly impossible to expect any more decrease after cholestasis. Thus, a dosage of PTZ was needed to increase the seizure activity in control group to an average stage that can be altered both positively and negatively by dithizone and bile duct ligation, respectively. According to some pilot studies (data not shown), the optimum dosage was 60 mg/kg. In another pilot study different time intervals (24, 48, 72 and 120 h) between bile duct ligation and PTZ-induced seizure were assessed to find the optimal time interval for the most effective inhibitory action of cholestasis on seizure activity. Based on the result of this preliminary study, the 24 h delay after bile duct ligation in assessing seizure activity was accompanied by the most decreasing effect on MSSS in this animal model of seizure (data not shown).
No significant difference was detected between Sham and control groups (Mann-Whitney U-test, P < 0.05), while this was not the case about BDL mice group compared to control and Sham groups (P < 0.05). As before, dithizone showed dramatic increase in the seizure activity (P < 0.01). Being injected to BDL mice, dithizone reversed the cholestasis-induced changes of seizure activity (i.e. decreased MSSS) and no difference was observed compared to control and Sham groups (P > 0.05), although it was not effective enough to decrease MSSS to the level of BDL group (P < 0.05) (Fig. 3A) .
3.5. Incidences of different seizure severity scores were decreased in BDL group, while these changes were eliminated by dithizone injection Fig. 3B shows the incidences of three different seizure severity scores in groups of experiment III. No difference was detected among control, vehicle-injected (DMSO) and Sham groups in any of these scores (Fisher's exact test, P > 0.05).
Score 3
Percentage of mice that showed seizure severity score 3 was higher in dithizone-injected mice compared to vehicle-injected group (P < 0.05). Compared to Sham group, BDL group resulted in lower incidence (P < 0.05), while its effect was decreased by dithizone administration, as dithizone-injected BDL mice had more score 3 incidence than BDL group.
Scores 5 and 6
Incidence of mice that showed score 5 was decreased in BDL group and increased after dithizone injection, although neither cholestasis nor dithizone injection resulted in significant changes (P > 0.05).
Dithizone highly enhanced the incidence of seizure severity score 6 in comparison with vehicle-injected group (P < 0.01). On the other hand, as control and Sham groups did not have any mouse with seizure severity score 6, cholestasis which was supposed to reduce the incidence of any score was not able to show any difference. However, dithizone-injected BDL mice did not show significant increase in the incidence of score 6 compared to Sham and BDL groups (P > 0.05), as the increasing effect of dithizone had been suppressed by cholestasis. Fig. 3 . Different indices (i.e. MSSS, incidence and FCL) show decreased seizure activity in BDL-mice, while this effect is suppressed by dithizone injection. DMSO and 60 mg/kg of PTZ were injected to vehicle and control groups, respectively. (A) Maximum seizure severity score increased in dithizone group (P < 0.05), decreased in BDL group (P < 0.05) and in dithizone-injected BDL group it was at the level of sham group (P > 0.05). (B) Percentage of mice responding with score 3, 5 and 6 seizures. (C) Forelimb clonus latency increased in BDL group while this enhancement was suppressed in BDL-mice which were injected dithizone intraperitoneally. * P < 0.05 and ** P < 0.01 compared to vehicle-injected group; + P < 0.05 and ++ P < 0.01 compared to control group; X P < 0.05 and XX P < 0.01 compared to sham-operated group; # P < 0.05 compared to BDL group.
Bile duct ligation increased forelimb clonus latency and this effect was decreased by dithizone injection
As discussed earlier, ''forelimb clonus latency'' was the interval between injection of PTZ and onset of seizure activity of score 3 or higher scores. Changes of FCL in the experiment III of the study are shown in Fig. 3C . No significant changes were caused by injection of vehicle (DMSO) and sham operation compared to control group (P > 0.05), whereas cholestasis prolonged FCL compared to sham group (P < 0.05). Dithizone, which did not change FCL significantly, after being injected to BDL mice reduced FCL.
Discussion
In this study, we evaluated the effect of zinc chelating agents on the seizure activity and assessed their ability to suppress the cholestasis-induced alteration in the seizure activity. Our data demonstrated that pretreatment with metal chelating agents, dithizone and DEDTC, resulted in a dramatic dose-dependent increase in the PTZ-induced seizure severity. On the other hand, we showed that cholestasis-induced decrease in MSSS and incidences of different seizure severity scores and increase in the forelimb clonus latency were diminished by dithizone injection.
The increased PTZ-induced seizure severity score in dithizoneinjected mice in a dose-dependent manner suggests that the overall effect of zinc is to dampen excitability. These preliminary data in our study are consistent with previous studies. Mitchell and Barnes 22 observed that intra-peritoneal injection of DEDTC in doses more than 50 mg chelates endogenous zinc and lowers the threshold of convulsion, when the rat hippocampal perforant pathway was stimulated. Furthermore, DEDTC and dithizone were found to augment the severity of kainic acid-induced seizures. 22 Also, mice knocked out for ZnT3 (the gene encoding for zinc transporter), which lacked histochemically reactive zinc in synaptic vesicles, were more susceptible than wild-type (ZnT3+/ +) mice to kainic acid-induced seizures. 27 All studies mentioned above indicate a protective role for endogenous zinc. Considering the fact that seizure activity is dependent on the balance between the excitatory (e.g. NMDA) and inhibitory (e.g. GABA A ) receptors, the best described inhibitory effects of zinc are the antagonistic effect on NMDA receptors [38] [39] [40] (and the enhancement of GABA release (perhaps by blocking GABAB autoreceptores) that produce giant depolarizing potentials in CA3 region. 41, 42 On the other hand, the present data revealed that the cholestasis-induced decrease in MSSS and incidences of different seizure severity scores and increase in the forelimb clonus latency were diminished by dithizone injection. This result suggests that the enhanced seizure threshold in cholstatic mice might be due to the changes in Zinc concentration or content. However, this hypothesis is warranted more detailed studies. One question which arises is that whether or not the enhancement of seizure activity by DEDTC and dithizone is due to the Zinc chelation or to other actions of these compounds. For example, DEDTC inhibits a variety of enzymes with crucial sulfhydryl groups. [43] [44] [45] However, this inhibition lasts for several hours whereas the effect of a single dose of DEDTC on the chelation of the histochemically reactive mossy fiber zinc is relatively short, less than an hour. 46 In the present study, we also evaluated the PTZ seizure activity shortly after injection of metal chelators. In addition, it has been shown that bursting of CA3 neurons in hippocampus can readily be obtained following stimulation of the mossy fibers after perfusion of hippocampal slices by DEDTC; replenishing the zinc in these slices prevents this effect of DEDTC. 23 Thus the most parsimonious explanation for the lowering of seizure threshold by these compounds appears to be chelation of zinc. However, it should be noted that Jones et al. in 1992 have shown that the zinc chelator DEDTC could induce a modest decrease in the biliary and urinary excretion of copper but not other trace elements such as magnesium, calcium and iron. 47 Therefore, more detailed studies are clearly needed to examine whether the dithizone-induced alteration in the seizure activity of cholestatic mice is due to its specific effect on the zinc content or not.
It is well known that cholestasis could result in several alterations among which, of our interest, are elevated hepatic and plasma levels of zinc, 33 NO overproduction in cholestatic condition 30, 31, 48 and increased plasma levels of endogenous opioids. 49, 50 On the other hand, some studies have reported that NO generators can produce accumulation of chelatable zinc. 28, 51, 52 Moreover, there is increasing evidence of the interaction between zinc and opioidergic system; Tejwani and Hanissian 35 reported that physiological concentrations of zinc were inhibitory to muopioid receptor binding. A recent study reported that cholestasisinduced increase in clonic seizure threshold was, in part, reversible by opioid antagonists and NOS inhibitors. 32, 37 Based on these reports, our finding of the effect of dithizone on cholestasisinduced changes of seizure activity suggests that in addition to NO and opioid systems zinc also plays a role in the cholestasis-induced seizure threshold. However, it remains to be explained whether alteration of zinc homeostasis follows either opioids or NO, or vice versa; as a result, further studies seem to be necessary. It is possible that markedly decreased permeability of bloodbrain barrier, which is well confirmed in cholestasis, 53 reduces the rate of passage of PTZ and can explain the increased lag phase before seizure in the BDL group in this study. This finding is in agreement with a previous study that also showed enhanced latency of the onset of seizure after bile duct ligation. 54 As dithizone could also decrease the increased latency of onset of seizure, it suggests a role for zinc in the function of blood-brain barrier.
Conclusion
In conclusion, the present study shows that bile duct ligation decreases seizure activity. As the effect of BDL on seizure activity is diminished by dithizone administration, elevated plasma levels of zinc and the possible increase in brain zinc content may have been involved. Our findings suggest a probable increase of zinc in cholestatic state which would play some role in cholestasisinduced alterations of seizure severity. These findings fulfilled our expectations of this study and encouraged us to stride for further studies in the hope of finding more evidence about the relations between cholestasis and zinc.
